Scientific advisory board

The Board of EBRP is advised by a Scientific Advisory Board (SAB) made up of specialists in the field of genetics, hematology, protein therapy, and dermatology. The SAB offers insight and guidance to applicants, fostering an environment that encourages research, collaboration, and ultimately accelerates progress towards a cure for EB. 

​The SAB has reviewed and recommended for funding applications in excess of $5.2 million dollars during 2016.  $2.6 million of that amount EBRP has directly funded and secured funding partners for the remaining $2.6 million. At EBRP we are on track to fund an additional $3.6 million in research in 2017 with the hope to raise $20 million dollars over the next 3 years to go towards treatments and therapies to dramatically improve quality of life for individuals with EB and ultimately a cure.

Anne Lucky , M.D.

Scientific Advisory Board Chair

​Medical Director of Epidermolysis Bullosa Center of Cincinnati Children's Hospital

Greg Barsh, M.D., Ph.D. 

Head of the Barsh Lab at the Hudson Alpha Institute for Biotechnology

Suephy Chen M.D., MS

Associate Professor of Dermatology at Emory University

Alain Hovnanian, M.D., Ph.D.

Professor of Medical Genetics and Director of an INSERM Department at Necker Enfants Malades Hospital

Christopher Sloey

Senior Scientist at Amgen Inc. working in Drug Product Technologies 

Amy Paller, M.D.

Chair of Department of Dermatology at Northwestern University and Chair of Skin Disease Research Center and Director of Pediatric Dermatology Clinical Research

Richard Azizkhan, M.D.

CEO of Omaha Children's Hospital Medical Center

Please click here to see full bios of the Scientific Advisory Board members. 

The application deadline for the next funding cycle is July 15, 2019. EBRP expects the SAB to have completed the evaluation and scoring of the submitted LOIs by the end of September 2019, after which applicants will be contacted with the results. More information on the grant application process can be found on the Applying for a Grant page.

Thank you to our 2018 Scientific Advisory Board Sponsor, Amicus Therapeutics